Market Index Logo
Mobile Menu Icon
☆
Watchlist
Log in
Sign-up
Fiji Kava Ltd (fij) Logo

Fiji Kava Ltd (FIJ)

___:___ · AUD
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

FIJ Chart

FIJ's Principal Activity is the the Group is a medical kava company based in Australia and has established a nucleus farm near Levuka, on the island of Ovalau, Fiji. The Company sells its range of TGA and FDA compliant Fiji Kava products online and in Australia, Fiji, New Zealand, China and the United States. The Company plans to conduct human clinical trials to test the efficacy of Fiji Kavas products and specific kava cultivars, targeting a range of medical conditions.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) +74.26%
vs ASX 200 (1yr) +57.78%

Size

Market Capitalisation
ASX Rank 1,828 of 2,295
Sector Rank 66 of 75

Key Information

Shares Issued
Sector Consumer Defensive
Similar Companies NGS / WNR / HCT
EPS -$0.026
DPS $0.00
NTA per share $0.03

Broker Consensus

FIJ is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Company Overview

Fiji Kava Limited (FIJ) is an Australian-Fijian medicinal kava health & wellness company, producing natural ‘noble kava' products for the complementary and alternative medicine market. Fiji Kava is focused on expanding the availability of noble kava products throughout western markets to provide a natural alternative to prescription medicines to promote sleep, soothe and calm the nerves, support muscle relaxation and relax the mind.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office West End QLD 4101
Website www.fijikava.com
Registry Automic Group
Auditor Hall Chadwick Audit (WA) Pty Ltd
Date Listed 20 Dec 2018

Upcoming Calendar (Forecasted)

Date Event
30/08/2021 Report (Prelim)
30/09/2021 Report (Annual)
17/02/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Dr Anthony Noble Chief Executive Officer,Managing Director May 2021 Director Bio icon

Dr Anthony Noble

Chief Executive Officer,Managing Director

Dr Noble has experience and background in the natural products and biotechnology industries. Dr Noble was appointed Managing Director and CEO of Australian Biotherapeutics in 2019. At Australian Biotherapeutics, Dr Noble contracted and commissioned a single use bioreactor facility in Queensland, which was built after securing government and investor funding, and a distribution contract in the USA. Dr Noble has domestic and international experience from his time at SFI Group, including as Managing Director of SFI Research Pty Ltd and Global Head of Innovation for SFI Group. Dr Noble was variously SFI Group's Head of North Asia, Business to Business and General Manager of the Group's Chinese Joint Venture. Dr Noble was involved in establishing and expanding business operations in Korea, Canada and the USA, while more recent roles have included close cooperation with partners in Indonesia. Prior to the SFI Group, Dr Noble's experience in the biotechnology industry included roles as both Principal Scientist and Marketing Manager for Cryosite Ltd, Australian Cord Blood Service, where he gained new business licenses and grew the division via healthcare practitioners and consumer marketing programs. Dr Noble earlier worked in the UK as lead inspector and regulation director for the Human Tissue Authority, the implementation of regulations for Advanced Therapy Medicinal Products, including cell and gene therapies, and represented the Authority on working groups in the European Medicines Agency and the MHRA.
Mr Jack Theseus Lowenstein Non-Executive Director Aug 2020 Director Bio icon

Mr Jack Theseus Lowenstein

Non-Executive Director

Mr Lowenstein is an experienced ASX listed company director, who also has corporate history in Fiji, where he was the co-founder of the country's first investment bank, Kontiki Capital Ltd. Mr Lowenstein is a director and shareholder in Kinetic and has invested in Fiji Kava both pre and post IPO. Mr Lowenstein is currently a director of ASX listed Morphic Ethical Equities Fund Ltd, which is managed by Morphic Asset Management, which he co-founded in 2012. Morphic Asset Management was acquired by Ellerston Capital in 2019. Prior to establishing Morphic, Mr Lowenstein spent 14 years with global stock investor Hunter Hall International, where he rose to become deputy chairman of the ASX listed parent company and a director of Hunter Hall Global Value Ltd. His career as a non-executive director began in 1997 when he joined the board of the iconic, but troubled ASX listed window furnishings company Kresta. In 1999, he joined the board of the embattled ASX listed global reinsurance company ReAC.
Mr Nicholas (NicK) Simms Non-Executive Director,Chief Executive Officer Sep 2019 Director Bio icon

Mr Nicholas (NicK) Simms

Non-Executive Director,Chief Executive Officer

Mr Simms has decades of experience as an FMCG sector and listed-company CEO roles, including with Bubs Australia, where he oversaw the transition of Bubs from a small private entity to an ASX300 company.
Dr Andrew Kelly Non-Executive Chairman,Non-Executive Director Dec 2018 Director Bio icon

Dr Andrew Kelly

Non-Executive Chairman,Non-Executive Director

Dr Kelly is Executive Director and Co-Founder of Bio Pacific Partners. He has experience across the Australian biotech scene. His 35-year career spans discovery science to success, focusing in equal measures on research, commercialisation and investment. Dr Kelly is currently Executive Director of Bio Pacific Investments Ltd (NZ) and Bio Pacific Partners Pty Ltd (Australia). He has previously been Director of Focus Genetics Ltd (NZ), Horizon Science Ltd (AU), Bio Pacific Ventures Ltd (NZ), Anzamune Ltd (NZ), CMP Therapeutics Ltd (UK), Wool Equities, Encoate Ltd (NZ), Cleveland Biosensors Ltd (AU), Inner Vision Ltd (NZ), Ultrafine Merino company Ltd (NZ), and Velvet Antler Research New Zealand Ltd (NZ). He is a member of the Due Diligence Committee.
Mr Zane Yoshida Non-Executive Director Dec 2018 Director Bio icon

Mr Zane Yoshida

Non-Executive Director

Mr Yoshida has experience over many decades in the kava industry. He is a Member of the National Codex Committee, Executive Committee Member of the Australia Fiji Business Council and the Fiji Kava Taskforce Committee, and Chair of the Fiji-based subsidiary of Fiji Kava, South Pacific Elixirs Ltd as well as join the Board of its US subsidiary,Fiji Kava Inc.
Mr Jay Richard Stephenson Company Secretary Feb 2018 Director Bio icon

Mr Jay Richard Stephenson

Company Secretary

Mr Stephenson has been part of business development for over 30 years, including approximately 26 years as Director, Chief Executive Officer, and Company Secretary of listed and unlisted entities in resources, manufacturing, wine, hotels and property. He has been part of business acquisitions, mergers, initial public offerings, capital raisings, and business restructuring, as well as managing all areas of finance for companies. Mr Stephenson is a Non-Executive Director of and Dragon Mountain Gold Limited since July 2011, Strategic Minerals Corporation NL since 2009, Stonehorse Energy Limited since July 2011, and a former Non-Executive Director of Doray Mining Limited (August 2009 to April 2019), Chairman, Non-Executive Director of Auctus Alternative Investments Limited (February 2011 - March 2019), Drake Resources Limited (2005 to December 2017) and Blina Minerals Limited (October 2016 to April 2019). He is a member of the Due Diligence Committee.
Show All Show more Icon

Director Transactions

FIJ directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
30/06/21 Zane Yoshida Transfer 1,700,000 $0.10 $170,000 Off-market transfer
23/06/21 Zane Yoshida Sell +50,000 $1.00 ($49,999) On-market trade
29/12/20 Zane Yoshida Buy +750,000 $0.10 $75,000 Off-market trade
22/12/20 Nicholas (NicK) Simms Issued 1,000,000 $0.11 $110,000 Issue of options
22/12/20 Jack Lowenstein Issued 750,000 $0.11 $82,500 Issue of options
05/08/20 Nicholas (NicK) Simms Buy +441,176 $0.057 $25,000 Conversion of convertible notes
05/08/20 Nicholas (NicK) Simms Exercise 1 $25,000.00 $25,000 Conversion of convertible notes
05/08/20 Nicholas (NicK) Simms Issued 1 $0.00 $0 Issue of securities
20/03/20 Andrew Kelly Buy +43,112 $0.035 $1,508 On-market trade
12/03/20 Zane Yoshida Transfer 20,000 $0.06 $1,200 Off-market transfer
12/03/20 Zane Yoshida Transfer 20,000 $0.06 $1,200 Off-market transfer
12/03/20 Zane Yoshida Buy +45,000 $0.066 $2,970 On-market trade
12/03/20 Zane Yoshida Buy +45,000 $0.066 $2,970 On-market trade
12/03/20 Zane Yoshida Transfer 20,000 $0.06 $1,200 Off-market transfer
12/03/20 Zane Yoshida Transfer 20,000 $0.06 $1,200 Off-market transfer
10/03/20 Zane Yoshida Buy +20,000 $0.075 $1,500 On-market trade
10/03/20 Zane Yoshida Buy +20,000 $0.075 $1,500 On-market trade
09/03/20 Andrew Kelly Buy +400,000 $0.076 $30,400 On-market trade
09/03/20 Andrew Kelly Buy +400,000 $0.076 $30,400 On-market trade
27/12/19 Andrew Kelly Buy +244,918 $0.075 $18,369 On-market trade
27/12/19 Zane Yoshida Buy +15,000 $0.089 $1,335 On-market trade
27/12/19 Nicholas Simms Issued 750,000 $0.075 $56,250 Issue of securities
29/03/19 Andrew Kelly Buy +74,000 $0.086 $6,371 On-market trade
19/03/19 Andrew Kelly Buy +10,001 $0.086 $860 On-market trade
12/03/19 Zane Yoshida Buy +19,755 $0.119 $2,346 On-market trade
11/03/19 Andrew Kelly Buy +29,245 $0.096 $2,812 On-market trade
Show All Show more Icon

Director Interests

The current holdings of FIJ directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Zane Yoshida 30/06/2021 51,714 12,965,314 N/A N/A
Nicholas (NicK) Simms 22/12/2020 0 441,176 1,750,000 0
Jack Lowenstein 22/12/2020 410,000 2,958,189 1,450,000 N/A
Jay Stephenson 11/08/2020 0 N/A N/A N/A
Andrew Kelly 30/06/2020 801,276 N/A 750,000 N/A
Anthony Noble N/A N/A N/A N/A N/A
Show All Show more Icon

Shareholder Info

Top 20 Shareholders About the Data

Data supplied by Morningstar and accurate on Sep 10, 2020.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Yoshida Holdings Pte Ltd 13,915,314 13.55%
Avanteos Investments Limited (Warczak Super fund a/c) 4,000,000 3.89%
National Nominees Limited 3,000,000 2.92%
One Managed Investment Funds Ltd (Strategic Global a/c) 2,731,482 2.66%
Kinetic Growth Fund 2,492,048 2.43%
Green Stream Commodity Traders Pte Ltd 2,449,179 2.38%
Ernest W Moody (Revocable a/c) 2,359,010 2.30%
Mr Toni Sinozic & Mrs Anka Sinozik 2,205,000 2.15%
Project 1 holdings Pty Ltd (Project 1 a/c) 1,989,000 1.94%
Mial enterprises Pty ltd (Dashian family a/c) 1,675,000 1.63%
Mr Bruno Grandelis (Bruno Grandelis a/c) 1,653,196 1.61%
JBS Investment Management Limited 1,600,000 1.56%
Great Southern flour Mills Pty Ltd 1,500,000 1.46%
James Stephen Tonkin 1,469,507 1.43%
Eppwood Investment Pty ltd (the Copplin super a/c) 1,416,115 1.38%
Mr Matthew Reede 1,311,111 1.28%
Mr Matthew Crawford Reede 1,261,176 1.23%
Citicorp Nominees Pty Limited 1,246,445 1.21%
Mial enterprises Pty Ltd (Dashian family a/c) i 1,085,052 1.06%
Tu investments Pty ltd (Tu family super fund a/c) 1,000,000 0.97%
Show All Show more Icon

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 22 422 358 473 134 1,409

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Zane Yoshida 30/06/2021 13,017,028 10.01
Project 1 Holdings Pty Ltd 11/03/2021 6,500,000 5.00

Shareholders Buying

12 month transaction history compiled from ASX announcements.

Date Name Bought Previous % New %
11-03-21 Project 1 Holdings Pty Ltd 6,500,000 -- 5.00

Shareholders Selling

12 month transaction history compiled from ASX announcements.

Date Name Sold Previous % New %
30-06-21 Zane Yoshida 1,750,000 11.4 10.01

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.073 30 June
2019 $0.08 28 June
Page Icon
FIJ Historical Price Data (CSV)
Up to 20 years of EOD share price history
Sign up to Download Secure Content Icon
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.